Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a phase I dose toxicity trial
Open Access
- 1 July 1992
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 66 (1), 204-210
- https://doi.org/10.1038/bjc.1992.243
Abstract
Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.Keywords
This publication has 27 references indexed in Scilit:
- FcεRII/CD23: The Low Affinity Receptor for IgEAnnual Review of Immunology, 1990
- Interleukin 4 receptors on normal human B lymphocytes: Characterization and regulationEuropean Journal of Immunology, 1990
- Intact, 45‐kDa (membrane) form of CD23 is consistently mitogenic for normal and transformed B lymphoblastsEuropean Journal of Immunology, 1990
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- Differential regulation of IgG1 and IgE synthesis by interleukin 4.The Journal of Experimental Medicine, 1988
- High affinity binding of human interleukin 4 to cell linesBiochemical and Biophysical Research Communications, 1987
- Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4).The Journal of Experimental Medicine, 1987
- Characterization of the human B cell stimulatory factor 1 receptor.The Journal of Experimental Medicine, 1987
- Identification of a T cell-derived b cell growth factor distinct from interleukin 2.The Journal of Experimental Medicine, 1982